Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

SELL
$25.89 - $29.73 $37,669 - $43,257
-1,455 Reduced 14.43%
8,630 $239,000
Q4 2023

Jan 29, 2024

BUY
$26.13 - $33.94 $263,521 - $342,284
10,085 New
10,085 $290,000
Q2 2023

Jul 25, 2023

BUY
$36.12 - $41.79 $36,914 - $42,709
1,022 Added 17.32%
6,924 $253,000
Q1 2023

May 01, 2023

BUY
$39.39 - $51.28 $67,514 - $87,893
1,714 Added 40.93%
5,902 $240,000
Q4 2022

Feb 09, 2023

BUY
$41.75 - $54.5 $174,849 - $228,246
4,188 New
4,188 $214,000
Q1 2022

May 13, 2022

SELL
$45.75 - $56.69 $433,298 - $536,910
-9,471 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$41.32 - $61.25 $391,341 - $580,098
9,471 New
9,471 $511,000
Q4 2020

Feb 16, 2021

SELL
$33.47 - $42.56 $152,455 - $193,860
-4,555 Closed
0 $0
Q3 2020

Oct 09, 2020

SELL
$31.75 - $37.25 $17,557 - $20,599
-553 Reduced 10.83%
4,555 $167,000
Q1 2020

May 11, 2020

SELL
$27.03 - $38.62 $8,163 - $11,663
-302 Reduced 5.58%
5,108 $162,000
Q4 2019

Jan 29, 2020

SELL
$32.92 - $37.36 $297,498 - $337,622
-9,037 Reduced 62.55%
5,410 $212,000
Q3 2019

Nov 14, 2019

SELL
$32.49 - $42.13 $28,103 - $36,442
-865 Reduced 5.65%
14,447 $519,000
Q2 2019

Aug 14, 2019

BUY
$36.98 - $41.52 $138,046 - $154,994
3,733 Added 32.24%
15,312 $663,000
Q1 2019

May 09, 2019

BUY
$37.5 - $41.2 $171,262 - $188,160
4,567 Added 65.13%
11,579 $492,000
Q3 2018

Nov 14, 2018

BUY
$34.47 - $41.81 $8,272 - $10,034
240 Added 3.54%
7,012 $309,000
Q2 2018

Aug 10, 2018

BUY
$32.98 - $35.16 $94,091 - $100,311
2,853 Added 72.8%
6,772 $246,000
Q4 2017

May 21, 2018

BUY
$33.26 - $35.29 $130,345 - $138,301
3,919
3,919 $142,000

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $148B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track Braun Bostich & Associates Inc. Portfolio

Follow Braun Bostich & Associates Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Braun Bostich & Associates Inc., based on Form 13F filings with the SEC.

News

Stay updated on Braun Bostich & Associates Inc. with notifications on news.